Abstract Following acute injury, the concerted action of resident and nonresident cell populations evokes wound healing responses that entail a temporary increase in inflammation, extracellular matrix production, and proliferation to ultimately restore normal organ architecture. However, chronic injury evokes a perpetuating wound healing response promoting the development of fibrosis, organ failure, and cancer. Recent evidence points toward toll-like receptors (TLRs) as important regulators of inflammatory signals in wound healing. Here, we will review the activation of TLRs by different endogenous and bacterial TLR ligands during wound healing, and the contribution of TLR-induced signals to injury, fibrogenesis, regeneration, and carcinogenesis. We will discuss the hypothesis that TLRs act as sensors of danger signals in injured tissue to switch the wound healing response toward fibrogenesis and regeneration as a protective response to imminent danger at the cost of an increased long-term risk of developing scars and cancer.
Background
The ability to respond to injury is a fundamental property of all multicellular organisms. Injury threatens organ function and integrity, and induces a rapid but highly complex wound healing response that serves to protect against imminent danger on the one hand and to restore tissue architecture on the other hand. In some species such as amphibians, wound healing responses can achieve both goals as demonstrated by almost complete regeneration after the loss of complete limbs. However, this regenerative capacity has largely disappeared in mammals, with large and chronic wounds often healing by fibrotic scarring rather than regeneration. Development of fibrosis in organs such as the liver, lung, heart, and kidney is accompanied by a progressive loss of function and represents a common and clinically highly relevant problem [1] [2] [3] [4] . Moreover, chronic and uncontrolled wound healing provides a microenvironment that gives rise to cancer supporting the hypothesis that certain types of cancers represent "wounds that do not heal" and a final stage of abnormal and uncontrolled tissue repair processes [5] . Understanding the signaling mechanisms that promote fibrogenesis and carcinogenesis in chronically injured tissues is therefore of considerable clinical interest. In addition to the size and chronicity of a wound, scarring is also determined by the presence of inflammation. Infection is an obvious cause for inflammation and may promote scarring. However, in many injured organs, inflammatory signals are activated even in the absence of infection. Signals induced by "sterile inflammation" are believed to play an important role in scar formation as evidenced by reduced scarring in mice that lack inflammatory cell types such as macrophages and neutrophils [6] .
Wound healing responses can be divided into three distinct yet sometimes overlapping phases [7] : a first inflammatory and fibrogenic phase, a second regenerative phase, and a third remodeling phase. In most organs, injury affects primarily the epithelial and endothelial compartments and triggers the release of antifibrinolytic mediators to induce blood clot formation and of proinflammatory mediators to initiate the infiltration of leukocytes. Infiltra-tion of leukocytes is the dominant event in the first phase of wound healing responses and serves at least two distinct functions: (1) Removal of dead cells by phagocytosis and (2) promotion of ECM deposition by releasing profibrogenic mediators that activate fibroblasts. In several organs, a subset of white blood cells can also differentiate into fibrocytes to promote ECM deposition [8] . Newly synthesized extracellular matrix provides mechanic stability and serves as a scaffold for organ regeneration. In the second phase, macrophages, fibroblasts, and pericytes secrete growth factors that promote epithelial proliferation and angiogenesis to restore organ mass and vessel formation to provide for nutritional requirements of newly formed tissue, respectively. In the final third phase, ECM is degraded, and ideally, normal organ architecture is restored. In chronic injury, ECM production outweighs its degradation thus favoring progressive ECM accumulation. Moreover, accumulating ECM is prone to undergo secondary changes such as cross-linking making it more resistant to degradation and favoring scar formation.
On a molecular level, a plethora of mediators are involved in the regulation of fibrogenic and regenerative signals following injury. The probably best-characterized promoters of fibrogenic signals are transforming growth factor beta (TGFβ) and platelet-derived growth factor (PDGF). TGFβ is mainly produced by macrophages and signals through the Smad pathway to promote fibroblast activation and collagen production [9] . PDGF isoforms primarily promote the proliferation myofibroblasts and thus expand the pool of ECM-producing cells [10] . The crucial role of PDGF and TGFβ in fibrogenesis has been demonstrated in various organs by modulating the levels of bioactive PDGF and TGFβ in vivo. Overexpression of PDGF and TGFβ promotes spontaneous fibrosis of the lung, liver, kidney, and pancreas [11] [12] [13] [14] , whereas inhibition of PDGF or TGFβ prevents hepatic and lung fibrosis [15] [16] [17] [18] . In addition to PDGF and TFGβ, a number of other mediators such as chemokines, angiotensin, leptin, IL-4, IL-6, and IL-13 play important roles in fibrogenesis [19] . A number of growth factors such as HGF, TGFα, EGF, epiregulin, amphiregulin are elevated following tissue injury and promote epithelial regeneration.
Despite their prominent role in fibrogenesis, the effects of TGFβ and PDGF cannot account for the inflammatory component of wound healing. Recent evidence points toward Toll-like receptors (TLRs), a family of receptors that regulate innate and adaptive immune responses, as important modulators of inflammation during wound healing responses. Toll-like receptors recognize pathogen-associated molecular patterns (PAMPs) and activate innate immune responses to eliminate pathogens. In addition to recognizing PAMPs, TLRs also recognize a class of endogenous molecules that are released from necrotic tissue termed damage-associated molecular patterns (DAMPs). Thus, TLRs appear to regulate inflammatory responses during wound healing under both sterile and nonsterile conditions. Here we will review the role of TLRs in tissue injury, fibrogenesis, and regeneration. We will discuss the hypothesis that TLRs serve as danger sensors in injured tissue and that activation of TLRs protects against imminent danger such as infection or organ failure, but carries an increased risk of scar formation and cancer development.
TLRs and TLR signaling
Toll-like receptors are a group of highly conserved molecules that allow the immune system to sense molecules that are present in most classes of pathogens such as bacteria and viruses, but not the host, and to coordinate defense mechanisms against these pathogens (see Fig. 1 ). The recognition of pathogen-associated molecular patterns (PAMPs) by TLRs is a cornerstone of innate immunity and provides a quick and highly efficient response to pathogens in both vertebrate and invertebrate species [20] . The human TLR family consists of currently ten members, which are structurally characterized by the presence of a leucine-rich repeat (LRR) domain in their extracellular domain and a Toll/interleukin (IL)-1 receptor (TIR) domain in their intracellular domain [21] . The existence of a large number of TLRs enables the innate immune system to discriminate between PAMPs that are characteristic of different microbial classes and launch specific defense mechanisms. TLR4 senses Gram-negative bacteria by binding lipopolysaccharide (LPS), a membrane component of Gram-negative bacteria. TLR2 heterodimers recognize cell membrane components of Gram-positive bacteria. TLR3 and TLR7 sense viral infections by recognizing double-stranded and single-stranded RNA, respectively. TLR9 recognizes nonmethylated CpG-containing DNA from bacteria and viruses. TLRs that mainly serve to detect bacterial LPS and lipoproteins are located on the cell surface. TLRs such as TLR3, TLR7, TLR8, and TLR9 that mainly recognize viral RNA and bacterial DNA are located in late endosomelysosomes in which these materials are processed, and host DNA is not present, thus avoiding aberrant self-recognition. Some TLRs such as TLR2 and TLR4 have been suggested to also detect endogenous ligands termed DAMPs that are released from injured and inflamed tissue. A wide range of DAMPs including HMGB1, hyaluronan, S100 proteins, heat shock protein 60, and the alternatively spliced extra domain A of fibronectin have been suggested to activate TLRs [22] . However, there is still ongoing controversy with regard to several endogenous ligands, as many of these ligands have either been purified in bacterial systems or have a high affinity to bacterial products such as LPS suggesting that bacterial products rather than the suggested ligands themselves mediate their TLR-activating effect [23] . Although each TLR detects specific ligands, many of the signaling molecules that mediate intracellular response are shared by the TLRs (see Fig. 1 ). All TLRs signal through one or two adapter molecules termed MyD88 and TRIF [21] . Whereas MyD88 is part of the signaling cascade of all TLRs except for TLR3, Trif only interacts with TLR3 and TLR4. MyD88-and TRIF-dependent pathways initiate the transcription of a specific set of genes involved in proinflammatory, antiviral, and antibacterial responses. MyD88 activates NF-κB, AP-1, p38, and IRF-7 signaling cascades, while TRIF activates NF-κB and IRF-3. MyD88 and TRIF mediate NF-κB activation through different mechanisms and kinetics thus leading to the upregulation of distinct target genes.
TLRs and TLR ligands in wound healing response TLR activation in wound healing appears to be mediated by two entirely different classes of ligands: (1) In organs such as the intestine, the skin and the liver that are in direct contact with microbiota and microbial products, tissue injury leads to 
Prevention of epithelial injury by TLRs
The lung and the intestine are the prototypical organs in which TLRs exert a cytoprotective role and prevent tissue injury under conditions of stress. In bleomycin-induced lung injury, TLR-and MyD88-deficient mice display an increased degree of lung injury despite reduced recruitment of inflammatory cells [26] . This was attributed to a lack of cytoprotective signals in the absence of TLR2/4 or MyD88. Blocking the endogenous TLR ligand hyaluronan by a peptide-based approach resulted in a pattern of lung injury that was highly similar to that of MyD88 and TLR2-TLR4-deficient mice. Lung-specific overexpression of hyaluronan synthase decreases lung injury [26] . In the intestine, the TLR4-MyD88 pathway plays a similar role and prevents intestinal epithelial injury following application of dextran sulfate sodium (DSS), as seen by the increased injury in TLR4-and MyD88-deficient mice [27, 28] . Interestingly, gut-sterilized mice display a similar increase in intestinal injury and DSS-induced death as MyD88-deficient mice suggesting that PAMPs from the commensal intestinal microbiota stimulate cytoprotective pathways in the intestine to prevent epithelial injury [28] .
Promotion of epithelial injury by TLRs
Ischemia-reperfusion injury represents the scenario in which a profound injury-promoting role of TLR2 and TLR4 has been most thoroughly established. The injury promoting effects of TLR4 manifest in almost all organs as seen by the protection of TLR4-mutant or deficient mice after hepatic, renal, cardiac, and cerebral ischemia-reperfusion [29] [30] [31] [32] suggesting a common mechanism by which TLR4 promotes injury. However, studies in chimeric mice have shown that the contribution of bone marrow to TLR4-dependent ischemia-reperfusion injury differs between organs. In hepatic ischemia-reperfusion injury, the injurypromoting effects of TLR4 are mediated by a bone marrowderived cell population [33] . In contrast, TLR4-mediated injury in renal ischemia-reperfusion injury depends on resident renal cell populations [30] . The chemotherapeutic agent cisplatin also induces renal injury in a TLR4-dependent manner [34] . Similar to renal ischemia-reperfusion injury, the TLR4-mediated cytotoxic effect in cisplatin-treated mice depends on resident cells of the kidney [34] . Thus, TLR4 appears to promote tissue injury through multiple bone marrow and non-bone marrow cell populations, possibly in an organ-specific manner. In the kidney, TLR2-deficiency protects from ischemia-reperfusion injury more efficiently than deficiency of MyD88 [35] . Since ischemia-reperfusion injury and cisplatin-induced cytotoxicity are primarily sterile, non-bacterial TLR ligands have been suggested to mediate TLR4 activation in this setting. The putative TLR4 ligand HMGB1 has been postulated to be an important mediator of ischemia-reperfusion injury. HMGB1 is rapidly upregulated in hepatic and renal ischemia-reperfusion injury [29, 30] . Antibody-mediated blockade of HMGB1 potently reduces hepatic injury after ischemia-reperfusion. Notably, HMGB1 blockade could not further reduce injury in TLR2-TLR4 double knockout mice suggesting that HMGB1 mediates its effects in ischemia-reperfusion injury through TLR2 and TLR4 [29] . Several other putative TLR4 ligands including hyaluronan and biglycan are upregulated in ischemia-reperfusion injury of the kidney, but their functional contribution to injury has not yet been characterized [30] . Alcoholic liver injury also depends on TLR4, but is mediated by LPS. The elevated levels of LPS in the portal circulation are due to an ethanol-induced disruption of the intestinal epithelial barrier and a subsequently enhanced intestinal permeability [36] . In animals continuously exposed to ethanol, liver injury is strongly reduced when the Gramnegative gut microflora is eliminated by antibiotics [37] or when TLR4 signaling is blocked genetically [38] . It is unclear whether the effects of chronic alcohol on other organs such as the heart are also mediated by LPS-TLR4-dependent signals or whether the unique anatomical location of the liver predisposes to LPS-mediated damage in this scenario.
Promotion of epithelial regeneration by TLRs
There is evidence from different organs that TLR ligands promote epithelial regeneration under many circumstances, but that this effect may be dose-dependent with higher concentrations mediating growth-suppressive responses and lower concentrations mediating regeneration. The liver has an astounding ability to regenerate, and after 70% partial hepatectomy, it can restore its mass within 7 to 10 days. Following partial hepatectomy, MyD88 is required for restoration of liver mass at early time points in one study [39] . However, the contribution of MyD88-dependent signals to regeneration appears to be moderate as MyD88-deficient mice displayed the same liver/body weight ratio as wild-type mice 96 h after post partial-hepatectomy in one study [39] and did not display a decreased hepatocyte proliferation at any time point when compared to heterozygous or wild-type mice in another study [40] . Interestingly, the most likely candidates to mediate MyD88-dependent regenerative signals such as TLR2, TLR4, TLR9, as well as IL-1R and IL-18R are not involved in liver regeneration [39, 40] . It is likely that the growth-promoting TLR ligand is derived from the intestinal microbiota as germ-free mice also display suppressed liver regeneration [41] . On the other hand, TLR4 activation by higher LPS doses can suppress liver regeneration suggesting that TLR signaling can modulate liver regeneration in both directions depending on the degree of TLR activation [41] [42] [43] . In the intestine, a TLR2/TLR4/MyD88 signaling cascade is required for the regeneration of epithelia following DSSinduced injury [27, 44] (see Fig. 2 ). This MyD88-dependent growth-promoting signal is transmitted through macrophages which, following injury, migrate toward intestinal crypts to stimulate the proliferation of epithelial progenitor cells [44, 45] . The key role of MyD88 in wound healing is further demonstrated by a study that found a markedly slower healing of excisional skin wounds in MyD88-deficient than in wild-type mice [46] . This delayed healing is characterized by slower contraction, a decreased rate of formation of granulation tissue, and a decreased density of blood vessels in the newly forming granulation tissue. However, the authors did not investigate whether there was simply less granulation tissue or whether reepithelization also decreased in MyD88-deficient mice. systemic LPS levels increase, most likely due to changes in the intestinal microbiota and changes in the intestinal barrier that promote increase bacterial translocation [52, 53] . TLR4-deficient mice display significantly decreased hepatic fibrogenesis in three different models of experimental fibrogenesis induced by bile duct ligation, CCl 4 injection, or thioacetamide treatment [53, 54] . The importance of bacterial TLR ligands in promoting liver fibrogenesis was demonstrated by a strong reduction of fibrogenesis in gut-sterilized mice [54] . Hepatic stellate cells are a direct target of LPS and are responsible for TLR4-dependent fibrogenesis as shown by in vivo LPS challenge and in vivo fibrogenesis studies in TLR-chimeric mice [54] . Notably, a recent study has identified a single nucleotide polymorphism that results in a T399I substitution and confers a significantly reduced risk for fibrosis progression in patients with chronic hepatitis C virus infection [55] . This polymorphism is associated with a reduced TLR4 responsiveness thus confirming the profibrogenic role of TLR4 in a clinically relevant setting. In contrast to TLR4, TLR2 has no major role in the promotion of hepatic fibrogenesis [54] . Mice lacking TLR9 also display a reduction of CCl 4 -induced liver fibrosis [56] . TLR9 is expressed in hepatic stellate cells and upregulates TGFβ1 and collagen expression in response to stimulation by CpG-DNA or apoptotic hepatocytes. Although it was concluded that TLR9 is activated by apoptotic hepatocytes to promote stellate cell activation and liver fibrosis, it cannot be excluded that TLR9 is also the target of profibrogenic bacterial products released from the intestinal microbiota. In the heart, TLR4 deficiency results in a reduction of left ventricular hypertrophy, cardiac fibrosis, and TGF-β expression after myocardial infarction [57] . In the vasculature, atherosclerosis entails remodeling processes that display similarities with wound healing and fibrogenesis in other organs such as infiltration of inflammatory cells, activation of myofibroblast-like cells, and accumulation as well as changes in the composition of ECM. Recent genetic studies in atherosclerosis-prone apoE-or low-density lipoproteinreceptor-deficient mice have revealed a central role for TLRsignaling in the development of atherosclerosis. Deletion of MyD88 results in a reduction in plaque burden of 60% [58] while deletion of TLR4 or TLR2 alone also leads to reductions in aortic lesion area of around 30% to 60%, respectively [58, 59] . Conversely, administrations of the TLR4 agonist LPS [60] or TLR2 agonist Pam 3 CSK 4 , accelerate atherogenesis significantly [59, 61] . A number of groups have described increased TLR4 expression in intimal lesions, predominantly on macrophages and endothelial cells. One group reported that human adventitial fibroblasts express TLR4 and that TLR4 activation induces the production of proinflammatory cytokines suggesting that activation of TLR4 in the adventitia may augment neointima formation [62] .
Promotion of fibrogenesis by TLRs
Macrophages not only express high levels of TLRs but also promote fibrogenesis in the liver [53, 63, 64] and the kidney [65] , and play a key role during early and late stage of atherosclerosis [66] . Thus, macrophages are prime candidates to promote fibrogenesis in response to TLR ligands. Overloading with free cholesterol causes cell death of macrophages within atheromas and has been suggested to be a critical event during later stages of atherogenesis [66] . Deficiency of TLR4 or MyD88 reduces free cholesterol-induced macrophage apoptosis, supporting a proatherogenic role of the TLR4-MyD88 signaling axis in atherosclerosis [67] . TLR2 expression on macrophages was required to mediate the atherogenic effects of the TLR2 ligand Pam 3 CSK 4 . However, in response to high fat diet, non-bone marrow-derived cells such as endothelial cells contribute to the proatherogenic effects of TLR2, whereas BM-derived cells do not promote TLR2-dependent atherosclerosis [59] . It was suggested that endothelial expression of TLR2 contributes to endothelial cell activation at lesionprone sites in the vasculature in early phases to promote macrophage infiltration, whereas TLR2 activation in macrophages exacerbates the proinflammatory milieu within the lesion [59] . A number of studies have also reported single nucleotide polymorphisms that are associated with a lower responsiveness of TLR4 to confer protection to atherosclerosis, but results between different studies have been contradictory, and the degree to which these polymorphisms protect from atherosclerosis still needs to be established [68] . In other organs such as the kidney and the lung, the role of TLRs has been investigated in tissue injury, but its potential role in fibrogenesis has not yet been addressed.
The available data suggest that the presence of TLR ligands during wound healing responses promotes healing by scarring rather than healing by regeneration. It is likely that the fibrogenic response serves as defense mechanism against imminent danger and that TLRs in fibroblasts function to sense this danger. Increases in fibrogenesis allow a faster wound closure and/or preservation of organ integrity and thus protect from infection and organ failure. However, these beneficial short-term responses come at the cost of increased long-term problems, especially when injury is chronic.
TLRs and TLR ligands in cancer
Already in the nineteenth century, Rudolf Virchow, one of the founding fathers of modern pathology, postulated a link between chronic inflammation and cancer [69] . This link is especially apparent in organs such as the liver and the stomach in which chronic inflammation induced by HBC and HCV, or Helicobacter pylori, respectively, leads to chronic injury, wound healing, and cancer. Accordingly, cancer has also been suggested to be "a wound that does not heal" [5] . This concept is further supported by the finding that a wound-like gene expression signature was present in many common human cancers [70] . Due to the important role in inflammation, tissue regeneration, and fibrogenesis, TLRs are likely candidates to mediate effects of the innate immune system on carcinogenesis. Although the role of TLRs in cancer is far from being completely understood, current results suggest a dual role of TLRs in cancer: Exceptionally high doses of TLR agonists appear to have an anticancer effect, whereas low doses of TLR agonists promote cancer growth.
Antitumor effects of TLRs
Antitumor effects of bacterial infections were first recognized by Busch and Bruns in the eighteenth and nineteenth century in patients with advanced cancers [71, 72] . Coley observed a considerable rate of tumor regression and even complete cure in larger sets of patients with sarcomas of the bone using "Coley's toxin," a mixture of heat-killed Streptococci and heat-killed Serratia marracens [73] [74] [75] . However, the mechanisms through which Coley's toxin induces tumor regression are still not understood, and it remains to be established whether TLRs are indeed required for the antitumor effect of this toxin, and whether it acts on TLRs in the immune system, the tumor, or the tumor vasculature. A recent study suggests that TLR4 and MyD88 play an important role in antitumor responses following chemotherapy and irradiation [76] . TLR4-deficient mice have significantly larger tumors after doxorubicin and oxaliplatin treatment or irradiation than wild-type mice, yet displayed similar growth rates in the absence of treatment [76] . Data from this study suggests that cell death induction by chemotherapy or irradiation induces the release of HMGB1 to subsequently trigger TLR4 activation in dendritic cells, enhance antigen presentation, and promote cytotoxic T-cell responses. This hypothesis is further confirmed by the finding that a mutation in the human TLR4 gene is associated with an increased frequency of metastasis in breast cancer patients after conventional chemotherapy [76] .
Tumor-promoting effects of TLRs
In contrast to the antitumor effects of bacterial infection or high-dose TLR agonists, low doses of LPS have been shown to enhance tumor growth and to decrease tumor apoptosis in adoptive transfer tumor models. Balb/c mice receiving a tail vein injection of 4T1 mouse mammary carcinoma cells show an increase in lung metastases when simultaneously injected with LPS [77, 78] . Similarly, tumor nodule numbers and lung weights are increased in response to LPS in mice that had been injected with colon adenocarcinoma cell line CT26 [79] . In this study, the tumor-promoting effects of LPS were not a result of direct actions of LPS in tumor cells, but depended on the presence of the LPS receptor TLR4 in the host as there was no LPSinduced NF-κB activation in tumors when CT26 cells were injected into mice expressing a nonfunctional TLR4. Using TNFα-chimeric mice, the authors demonstrated that LPS induces the release of TNFα in bone marrow-derived cells to induce NF-κB and tumor growth [79] . In another study, injection of Listeria monocytogenes promoted tumor growth in mice that were subcutaneously injected with the hepatocarcinoma cell line H22 [80] . Knockdown of TLR2 but not TLR4 in H22 tumor cells abrogated the growth promoting effects of L. monocytogenes. These studies strongly suggest a role for TLR ligands in promoting carcinogenesis, but have a number of limitations such as the unphysiologic tumor and tumor microenvironment of adoptive transfer models as well as the focus on only one or two TLR ligands.
A number of recent studies have investigated carcinogenesis in mice deficient in TLRs or TLR adapter molecules using models of inflammation-associated cancer. These models cover all stages from tumor initiation to tumor promotion and provide a physiological tumor environment thus accounting for a possible role of TLRs in stroma-tumor interactions, possibly mediated by endogenous TLR ligands released from necrotic tumor cells. In patients with ulcerative colitis and colon cancer as well as in a murine model of inflammation-associated colon cancer, azoxymethane plus DSS, TLR4 expression is strongly upregulated in the epithelial compartment of tumors [81] . Moreover, TLR4-deficient mice display a profoundly reduced dysplasia, number and size of tumors [81] . Similar results were reported in a study that investigated the role of MyD88 in colon cancers. MyD88 deficiency leads to decreased carcinogenesis in Apc Min/+ mice, a noninflammatory model of colon cancer, as well as in the azoxymethane model [82] . Absence of MyD88 reduces the size and number of polyps. Although polyps showed the same degree of proliferation in Myd88-deficient and wt mice, there was more apoptosis in polyps from the MyD88-deficient mice. In the liver, MyD88-and IL-6 deficiency significantly reduce tumor load in male but not female mice in the model of diethylnitrosamine (DEN)-induced hepatocellular carcinomas [83] . The authors of this study demonstrated that necrotic hepatocytes stimulate Kupffer cells through a MyD88-dependent pathway to induce IL-6 production which promotes liver injury and compensatory proliferation. However, a recent follow-up study identified the IL-1R as upstream mediator of MyD88-dependent tumor-promoting signals as demonstrated by the decreased IL-6 levels and tumor load in IL-1R-deficient mice [84] . In the liver, TLR4 and MyD88 are required for the develop-ment of fibrosis [53] , a first stage toward the development of hepatocellular cancer in patients with chronic hepatitis. Thus, it is likely that fibrosis-associated HCC is promoted by the TLR4-MyD88 pathway. As the DEN infant mouse model of hepatocellular cancer only induces a small degree of inflammation and no overt fibrosis, it is possible that nonfibrotic HCC and fibrosis-associated HCCs may both be MyD88-dependent but mediated by distinct yet not mutually exclusive molecular mechanisms, i.e., an IL-1R-dependent pathway in nonfibrotic HCC and a TLR4-dependent pathway in fibrosis-associated HCC.
Signaling mechanisms by which TLRs modulate injury and wound healing
Antiapoptotic signals Toll-like receptors are potent activators of the NF-κB pathway [21] . NF-κB regulates the transcription of several hundred genes with κB sites, among them a number of antiapoptotic genes such as Bcl-2, iNOS, c-Flip, IAPs, and Traf molecules [85] . There is increasing evidence that TLRs provide signals to promote the survival of epithelial cells under stress conditions. However, it is not entirely clear whether the antiapoptotic effects of TLRs are directly activated in epithelial cells or whether TLRs stimulate other cell populations which then secrete factors to activate NF-κB and prevent apoptosis in epithelial cells. The lung and the intestine are the prime examples in which a cytoprotective effect of TLRs in epithelial cells has been demonstrated. The activation of NF-κB by a TLR2/TLR4/ MyD88-dependent pathway is required to protect from bleomycin-induced apoptosis as demonstrated by an increase in epithelial cell apoptosis in the lung of TLR2/ TLR4 double-deficient and MyD88-deficient mice [26] . In the lung, the endogenous TLR2/TLR4 ligand hyaluronan provides an important signal to activate this TLR-dependent NF-κB response [26] . In the intestine, TLR signaling is required for the maintenance of intestinal epithelial homeostasis and protection from injury. TLR2-, TLR4-, and MyD88-deficient mice show an increased mortality and increased epithelial injury in response to DSS [27, 28] . In comparison to wild-type mice, MyD88-deficient mice display a strong decrease of cytoprotective factors such as IL-6, KC-1, hsp25, and hsp72 [28] . Moreover, Cox2 levels are decreased in MyD88-and TLR4-deficient mice. The decreased level of Cox2 is correlated with an increased level of apoptosis after DSS. As Cox2 is known to be an NF-κB target and a mediator of antiapoptotic, proliferative, and tumor-promoting effects in the colon, it appears that the a TLR4-MyD88-NF-κB-Cox2 axis is involved in protection from apoptosis in normal as well as premalignant cells of the colon [27] .
Cell death promoting signals While TLRs promote protection from injury under some circumstances, they can also promote tissue injury under different circumstances, mostly under conditions of extreme stress. Very high doses of LPS alone, e.g., in patients with septic shock, or high doses of LPS in combination with priming events, e.g., infection with certain bacterial strains such as Propionibacterium acnes, result in significant cell death [86] . Necrotic tissue injury, especially after ischemiareperfusion injury, is another setting in which TLRs have been implicated in the promotion of cell death. In this setting, cytotoxic effects of TLRs appear to be the result of an increased recruitment of bone marrow-derived inflammatory cells which further promote injury. In contrast to apoptosis, necrosis triggers a strong inflammatory response which may, at least in part, be mediated by TLRs and the putative TLR ligand HMGB1. Scaffidi and colleagues reported that challenge of monocytes with necrotic HMGB1 −/− cells reduces TNFα production by 75% in comparison to challenge with necrotic HMGB1 +/+ cells [87] . HMGB1 also has a moderate effect on neutrophil recruitment as seen by a 37% reduction of neutrophil recruitment in mice treated with a neutralizing HMGB1 antibody after acetaminophen-induced liver injury [87] , and an approximately 30% reduction of neutrophil recruitment after intraperitoneal injection with HMGB1 −/− cells in comparison to mice injected with HMGB1 +/+ cells. [88] . Ischemia-reperfusion injury is the best characterized setting in which TLR4 acts as a central mediator of injury as demonstrated by the protection of TLR4-mutant or TLR4-deficient mice after hepatic, renal, cardiac, and cerebral ischemia-reperfusion [29] [30] [31] [32] . In ischemia-reperfusion injury, the endogenous TLR4 agonist HMGB1 seems to be the predominant activator of TLR4 [29] . HMGB1 levels are increased shortly after ischemia-reperfusion and blockade of HMGB1 by a neutralizing antibody reduces injury in wild-type but not TLR4-deficient mice. In hepatic ischemiareperfusion injury, TLR ligands such as HMGB1 do not directly activate pro-apoptotic signaling pathways in target cells but through bone marrow-derived inflammatory cells as elegantly shown in chimeric TLR4 mice [29] . Dendritic cells are the most likely candidate to mediate injury following ischemia-reperfusion injury. After hepatic ischemiareperfusion, wild-type but not TLR4-mutant dendritic cells displayed a strong increase of TNFα production [89] , a wellknown mediator of hepatic IR injury that is rapidly and potently released from monocytic cells such as macrophages and dendritic cells following TLR activation [90, 91] . Therefore, the most likely scenario is that HMGB1 is released from necrotic parenchymal cells to activate TLR4 on dendritic cells which in turn release TNFα to promote tissue injury. The role of the HMGB1 and dendritic cell-dependent pathway in ischemia-reperfusion injury has not been established for other organs, and it is possible that other TLR4 ligands and cellular targets contribute to injury in these organs. In alcoholic liver injury, increased exposure to ethanol induces hepatocellular necrosis which is largely dependent on Kupffer cells as demonstrated by reduced injury in Kupffer cell-depleted mice [92] . Hepatocellular injury by ethanol appears to depend on NF-κB activation and subsequent release of toxic mediators such as TNFα by TLR4-activated Kupffer cells [38, 93] . As mice deficient in the NADP(H) oxidase component p47 display substantially reduced NF-κB activation, TNFα induction, and liver injury, NADP(H) seems to link the LPS-induced TLR4 activation and the release of cytotoxic mediators such as TNFα [94] . It is likely that the effects of LPS synergize with direct effects of ethanol on the liver to promote injury.
Growth-promoting and angiogenic signals
There is evidence that TLR receptors are involved in the regulation of epithelial proliferation and angiogenesis following injury. The best example for growth promoting effects of the TLR-MyD88 signaling cascade is the intestine, where a TLR2/TLR4/MyD88 signaling cascade is required for the regeneration of epithelia following DSSinduced injury [27, 44] . This TLR4-MyD88-dependent growth-promoting signal is transmitted through cyclooxgynease 2 (Cox2)-expressing macrophages migrate toward intestinal crypts to stimulate the proliferation of epithelial progenitors [45] . Prostaglandin E2 appears to be one crucial growth-promoting signal provided by macrophages stimulated through the TLR4-MyD88 pathway. After DSS injury, Cox-2 expression was increased in wild-type, but not TLR4-deficient mice [27] . Moreover, exogenous prostaglandin 2 supplementation of TLR4-deficient mice completely restored the defective proliferation. The mechanism for improved epithelial repair may be through prostaglandin E2-dependent activation of the epidermal growth factor receptor (EGFR). It is known that prostaglandin E2 transactivates the EGF receptor [95] . Accordingly, inhibitors of Cox-2 and EGFR tyrosine activity decreased LPS-induced proliferation in a human intestinal cell line [27] . In the liver, deficiency of MyD88 delays the expression of growth promoting genes such as c-fos, c-jun, JunB, and c-myc and suppresses the activation of NF-κB [39, 40] . It remains unclear which TLR mediates the above decribed MyD88-dependent regenerative responses as different TLR knockout mice as well as mice deficient in IL-1R and IL-18R receptor signaling did not display these defects [39] .
The TLR4-MyD88 signaling axis is also involved in the regulation of angiogenesis to restoring blood flow to the site of injured tissue, a prerequisite for mounting a successful repair response. In skin wounds, absence of MyD88 results in slower wound healing, decreased angiogenesis, and decreased VEGF levels, albeit by a minor extent [46] . However, it seems unlikely that the rather small decrease in VEGF production is responsible for the striking reduction of skin wound healing in MyD88-deficient mice, and it is likely that other VEGF-independent mechanisms such as decreased fibroblast activation or decreased re-epithelization are additionally involved. TLR4 activation alone is not sufficient for the induction of VEGF, but requires the presence of adenosine [96] . Promotion of angiogenesis by TLR4 therefore appears to be restricted to specific pathophysiological circumstances. TLR4-mediated increase of VEGF production is largely mediated by a transcriptional upregulation of HIF1α which binds to a known hypoxia response element in the VEGF promoter [96] . The potential regulation of angiogenesis by the TLR pathway is further supported by a study that has linked downstream mediators of TLRs such as TBK1, TRIF, and IRF3, to hypoxia-induced VEGF, FGF1, and FGF2 expression and angiogenesis [97] .
Profibrogenic signals
Fibrosis-promoting signals can either directly target fibroblasts or cells such as macrophages to indirectly promote fibroblast activation. Despite the high level of TLR expression in macrophages, there is accumulating evidence that TLRs directly target fibroblasts to induce activating signals. One main mechanism by which TLRs modulate fibrogenic responses is through the TGFβ signaling pathway. Hepatic stellate cells, the main precursor of fibroblasts in the liver, functionally express TLR4. Activation of TLR4 sensitizes hepatic stellate cells toward the effects of TGFβ, and thereby, promotes TGFβ-dependent activation and collagen production [53] . This effect is mediated by the downregulation of an inhibitory TGFβ pseudoreceptor, Bambi. Bambi is a type I TGFβ receptor that lacks an intracellular kinase domain and thus acts an inhibitor of BMP, activin, and TGFβ signaling [98] . A recent report has shown that Bambi is dispensable for normal development as demonstrated by the unaltered phenotype of Bambi-deleted mice [99] suggesting that Bambi's main function may not lie within the regulation of BMP family member signaling in development but in the regulation of BMP family member signaling in disease processes. In hepatic stellate cells of the normal liver, Bambi is highly expressed to presumably restrict TGFβ-and BMP-induced signals. TLR4-mediated downregulation of Bambi allows for unrestricted activation of the TGFβ pathway in hepatic stellate cells (see Fig. 3 ). Bambi downregulation is mediated through a MyD88-dependent and Trif-independent pathway [53] . Accordingly, suppression of liver fibrosis is much stronger in MyD88-than in Trif-deficient mice. Interestingly, hepatic fibrogenesis strongly downregulates Bambi expression in hepatic stellate cells from wild-type mice but not TLR4-mutated mice [53] . These results are consistent with the hypothesis that increases in LPS during hepatic fibrogenesis induce a downregulation of Bambi. While hepatic stellate cells display a more than 50-fold higher expression of Bambi than whole liver (AM and RFS, unpublished data), the expression and role of Bambi in fibroblasts and fibroblast precursors are not known. It is conceivable that Bambi acts as a repressor of TGFβ signaling in all fibroblast populations or that hepatic stellate cells have developed high Bambi expression as a result of their unique function and anatomical localization.
In addition to sensitizing toward TGFβ-induced signals, TLRs promote proinflammatory and antiapoptotic signals in fibroblast populations [50, 100] . NF-κB is a key proinflammatory and antiapoptotic transcription factor and is activated by TLRs in fibroblast populations [50, 100] . In the liver, NF-κB activation has been suggested to promote the survival of hepatic stellate cells and development of hepatic fibrosis [101, 102] . There is only little information on the role of TLRs in macrophages during fibrogenic responses. TLR4 on BM-derived cell populations does not promote hepatic fibrogenesis [39] , but it is conceivable that TLRs on macrophages from other organs might promote fibrogenesis by either upregulating the secretion of TGFβ or other mediators.
Conclusions and outlook
Eleven years after the cloning of the first human TLR, TLRs have emerged as key regulators of inflammation with a broader role in acute and chronic inflammatory processes than initially perceived. In addition to their important role in innate immunity, TLRs are involved in the regulation of tissue injury and wound healing process even under sterile conditions. The ability of TLRs to recognize endogenous mediators appears to be key to their ability to regulate sterile inflammation after acute injury in many organs. Despite rapid progress in understanding the broad role of TLRs in the pathophysiology of disease, a number of questions remain to be answered: (1) There is no satisfying explanation why TLRs exert opposing effects on injury and wound healing in different organ systems. The most likely scenario is that there is already a sufficient activation of cytoprotective pathways in some organs, e.g., in the liver after ischemia-reperfusion and that activation of cytoprotective pathways by TLRs does not provide additional benefit in these organs, whereas TLRs act as key mediators 
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